Title |
Chromophobe renal cell carcinoma with prolonged response to targeted therapy: a case report
|
---|---|
Published in |
Journal of Medical Case Reports, April 2012
|
DOI | 10.1186/1752-1947-6-115 |
Pubmed ID | |
Authors |
Vasiliki Michalaki, Constantine Gennatas |
Abstract |
Chromophobe renal cell carcinoma is universally accepted as a distinct subtype of renal cell carcinoma. There are conflicting reports on prognosis, and few data on response to treatment exist. Currently, we do not have any effective treatment for the metastatic disease apart from surgical procedures. Current strategies are based on results obtained in the context of clear cell-type renal cell carcinoma. Separate trials for rare histologies seem unfeasible and are unlikely to be performed. For these cases, clinical observations are an important part for advancing therapeutic insight. In recent years, novel tyrosine kinase inhibitors have been shown to have significant clinical benefit in advanced renal cell carcinoma. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 9 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 3 | 33% |
Student > Ph. D. Student | 1 | 11% |
Researcher | 1 | 11% |
Student > Doctoral Student | 1 | 11% |
Unknown | 3 | 33% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 4 | 44% |
Agricultural and Biological Sciences | 1 | 11% |
Nursing and Health Professions | 1 | 11% |
Unknown | 3 | 33% |